Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
  • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants

Definitions

• compositions for the treatment of depression or symptoms suggesting depression are provided.
• the present invention relates to the administration of pharmaceutical preparations containing the active ingredient famotidine, in the treatment of depression or symptoms suggesting depression. Moreover, the invention also relates to cases with acid related diseases. Recently, depression can be regarded as an epidemic affecting the whole population all over the world. According to a national representative assay in Hungary (Kopp M. et al, Lege Nrtis Med. 7(3): 136-144, 1997), symptoms of depression occurred in 24.3% of the population in 1988, while this number turned out to be 30.6% by 1995. The information that in 1988 only 2.9% of the population was affected by depression of the severity that required therapy, while this figure was already 7.1% in 1995, is of even higher value. These data clearly demonstrate that the sudden increase, especially in the number of the patients requiring therapy, brought into focus the need of medicinal therapy and the launching of more specific medicines.
• ranitidine One of the most successful members of the group of H 2 -receptor antagonists is ranitidine, and the original medicine containing this active ingredient is presently marketed by the name of Zantac (Glaxo Wellcome).
• Zantac Zika Wellcome
• Billings and Stein Am. J. Psychiatry, 143, No.7, 915-15, 1986 have reported that the development of depression could be unquestionably associated with ranitidine- therapy in several cases. As a matter of fact, the manifest symptoms disappeared after terminating the administration of rantidine.
• Famotidine the molecule launched after ranitidine, is the active ingredient of several pharmaceutical preparations (Pepcid ® -Merk, Quamatel ® -Richter Gedeon, Gaster ® - Yamanouchi).
• famotidine has a similar gastrointestinal efficacy as ranitidine, but associated with less and milder adverse reactions.
• Pharmaceutical guides do mention however depression as one of the adverse reactions related to the administration of famotidine (Physicians' Desk Reference, 1999., page 1854.).
• the majority of publications made in psychiatry and worthy of mentioning are case studies, which report that famotidine is effective in the management of schizophrenia.
• famotidine has a more beneficial effect in the treatment of gastrointestinal complaints due to the milder and less frequent occurrence of adverse reactions.
• famotidine resulted in a significant reduction both in the values of depression and anxiety in the study population.
• the positive change was significant in the case of the symptoms suggesting depression, not only in comparison with the ranitidine-group, but also in comparison with the baseline values, i.e. famotidine had a significantly detectable antidepressant effect.
• the invention relates to the human therapeutic application of famotidine and its salts in the treatment of depression or symptoms suggesting depression, including somatic depression, unipolar depression, functional illnesses of psychic origin, atypical depression, dysthymia, bipolar affective disorder, seasonal depression and persistent mood disorder. Furthermore, the invention also relates to the application and the manufacturing of such a pharmaceutical composition.
• patients received medicinal therapy for a period of four weeks, i.e. they either received Quamatel ® (famotidine) tablets in a daily dose of 2x20 mg, or Zantac ® (ranitidine) tablets in a daily dose of 2x150 mg.
• the number of cases investigated was 119, which assured that the obtained data reach the level of statistical significance.
• the psychiatrist - who had no information regarding the treatment group the patient was assigned to - had performed the evaluation according to the Hamilton 24 (HAMD) depression scale, the Montgomery- Asberg (MADRS) depression scale or the Hamilton (HAMN) anxiety rating scale. During the statistical evaluation a probability level of p ⁇ 0.05 was regarded as significant.
• Multicenter, randomized, controlled study the study can be regarded blind with respect to the psychiatrist's assessment of the results.
• H.pylori eradication Severe hepatic insufficiency, inadequate cooperation, pregnancy, lactation, alcoholism, influenza, known hypersensitivity to ranitidine or famotidine, ulcer necessitating H.pylori eradication, pneumonia, meningitis, diabetes mellitus, anemia, hypertension, neuroleptics, acute hepatitis, epilepsy, endocrinological diseases, psychiatric treatment due to depression, antidepressant pharmaceutical therapy, cerebrovascular diseases, tumors, Parkinson's-disease, cerebral commotion, dementia, the use of H 2 -receptor blockers within the past month.
• H 2 -receptor blockers The depression altering effects of H 2 -receptor blockers have been assessed on the basis of the overall scores obtained by the HAMD and the MADRS depression scales prior to treatment and following the 4-week therapy.
• HAMA Hamilton anxiety rating scale
• the global parameters were assessed by applying the median-test (SAS NPARIWAY method).
• Tablets are prepared from the active ingredient famotidine by the method of direct pressing.
• the listed amount of ingredients are homogenized in the form of a powder (gross weight: 150g), then it is filled into a tablet press to give 1000 tablets.
• the individual weight of the tablets is 150 mg, and the active ingredient content is 20 mg famotidine.

Landscapes

• Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Biomedical Technology (AREA)
• General Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Epidemiology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Pain & Pain Management (AREA)
• Psychiatry (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Hydrogenated Pyridines (AREA)
• Medicinal Preparation (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Publications (2)

Family

ID=89978380

Family Applications (1)

Country Status (10)

Cited By (2)

Families Citing this family (3)

Family Cites Families (4)

• 2000
  • 2000-06-06 HU HU0002154A patent/HUP0002154A3/hu unknown
• 2001
  • 2001-06-06 AT AT01943711T patent/ATE302000T1/de not_active IP Right Cessation
  • 2001-06-06 AU AU2001266242A patent/AU2001266242A1/en not_active Abandoned
  • 2001-06-06 WO PCT/HU2001/000065 patent/WO2001093863A2/en not_active Ceased
  • 2001-06-06 DE DE60112750T patent/DE60112750T2/de not_active Expired - Lifetime
  • 2001-06-06 ES ES01943711T patent/ES2247137T3/es not_active Expired - Lifetime
  • 2001-06-06 EP EP01943711A patent/EP1289520B1/en not_active Expired - Lifetime
  • 2001-06-06 US US10/297,280 patent/US20040010021A1/en not_active Abandoned
  • 2001-06-06 JP JP2002501436A patent/JP2003535133A/ja not_active Withdrawn
  • 2001-06-06 DK DK01943711T patent/DK1289520T3/da active

Also Published As

Similar Documents

Legal Events